Dr MeiLan Han, of the University of Michigan, Ann Arbor, highlights studies in chronic obstructive pulmonary disease (COPD) presented at the CHEST 2021 Annual Meeting. Dr Han first reports on a study ...

Discover how machine learning is helping researchers identify different groups of chronic obstructive pulmonary disease (COPD ...

Eosinophil Granulocytes COPD Patients with COPD who exhibit low blood eosinophil counts had no change in exacerbations or survival compared with patients with typical counts. Patients with chronic ...

Inhalers Single-inhaler triple therapy is associated with a favorable benefit-risk profile compared with dual therapy for patients with symptomatic COPD and a history of exacerbations. Single-inhaler ...

Budesonide-formoterol inhaler was as effective as fluticasone-salmeterol in reducing the incidence of moderate-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) who ...

MERCY MEDICAL CENTER. 57 YEAR OLD STEPHANIE HARRIS HAS BOTH ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE, OR COPD. I STARTED SMOKING AROUND THE AGE OF 14 OR. 15. AND I COMPLETELY STOPPED MAYBE ...

Chronic lower respiratory diseases, including chronic obstructive pulmonary disease (COPD), are the sixth leading cause of death in the United States, according to the U.S. Centers for Disease Control ...

A Johns Hopkins Medicine-led analysis of medical information gathered on a diverse group of almost 250,000 people over four years has significantly clarified the link between the "exclusive" use of ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the Regeneron-partnered drug failed one of a pair of phase 3 chronic obstructive pulmonary ...

Many people with chronic obstructive pulmonary disease (COPD) experience severe fatigue that can limit their ability to perform daily activities. A 2021 review found fatigue was a symptom of COPD in ...

- Data presented show maintained or improved responses in multiple efficacy endpoints among patients treated with sotatercept plus stable background therapy for up to 48 weeks - - Patients receiving ...